Radiopharmaceuticals pluvicto / lutathera
Active Awarded Last action
- Contract number
- 36C25026N0310
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $2,423,133
Award facts
- Contract value 100% obligated
- $2,423,132.82 Current and potential, with all options
- Completion date 78% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
Novartis Pharmaceuticals Corporation received a $2.42M firm fixed-price delivery order from Veterans Integrated Service Network 10 (VISN 10) on February 1, 2026, for the supply of radiopharmaceuticals PLUVICTO (Lutetium Lu-177 Vipivotide Tetra) and LUTATHERA (Lutetium Lu-177 dotatate). The contract, which extends through December 31, 2026, will be performed in East Hanover, New Jersey, and was awarded without small business set-aside protections. This delivery order is issued under Novartis' existing single-award Blanket Purchase Agreement with VISN 10, valued at $7.48M and effective through September 30, 2030, which was established to support ongoing procurement of specialized radiopharmaceutical cancer therapies for the Veterans Affairs healthcare system.
These radiopharmaceutical products support advanced oncology treatments and nuclear medicine applications across the Department of Veterans Affairs healthcare network, addressing specialized cancer therapy needs for veteran populations. Novartis, a large foreign-owned pharmaceutical manufacturer, competes directly in federal procurement as a major supplier of innovative cancer treatments and diagnostic radiopharmaceuticals to VA and Defense Health Agency customers through multiple delivery vehicles, including blanket purchase agreements and indefinite delivery contracts with ceiling values exceeding $26M.
Quick answers
Who was awarded contract 36C25026N0310?
36C25026N0310 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 10 (Veterans Health Administration) on February 1, 2026.
How much is contract 36C25026N0310 worth?
The government has obligated $2,423,133 on 36C25026N0310.
Is contract 36C25026N0310 an order under another contract?
Yes. 36C25026N0310 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25026N0310 competed?
The extent of competition for 36C25026N0310 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award